Kobayashi Pharmaceutical Co (4967) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4967 Analyst Ratings

Moderate Sell

0 Buy

0 Hold

1 Sell

Based on 1 analysts giving stock ratings to

Kobayashi

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4967 Stock 12 Month Forecast

Average Price Target

¥5,281.00

▼(-1.62% Downside)

Based on 1 Wall Street analysts offering 12 month price targets for Kobayashi Pharmaceutical Co in the last 3 months. The average price target is ¥5,281.00 with a high forecast of ¥5,281.00 and a low forecast of ¥5,281.00. The average price target represents a -1.62% change from the last price of ¥5,368.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5066":"¥5,066","5679":"¥5,679","5219.25":"¥5,219.3","5372.5":"¥5,372.5","5525.75":"¥5,525.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5281,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥5.28K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5281,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.28K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5281,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥5.28K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5066,5219.25,5372.5,5525.75,5679],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5383,5375.153846153846,5367.307692307692,5359.461538461538,5351.615384615385,5343.7692307692305,5335.923076923077,5328.076923076923,5320.2307692307695,5312.384615384615,5304.538461538462,5296.692307692308,5288.846153846154,{"y":5281,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5383,5375.153846153846,5367.307692307692,5359.461538461538,5351.615384615385,5343.7692307692305,5335.923076923077,5328.076923076923,5320.2307692307695,5312.384615384615,5304.538461538462,5296.692307692308,5288.846153846154,{"y":5281,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5383,5375.153846153846,5367.307692307692,5359.461538461538,5351.615384615385,5343.7692307692305,5335.923076923077,5328.076923076923,5320.2307692307695,5312.384615384615,5304.538461538462,5296.692307692308,5288.846153846154,{"y":5281,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5678.791,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5394.361,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5477.728,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5221.741,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5187.413,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5236.65,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5273.235,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5367.171,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5249.504,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5067.566,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5168.423,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5428,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5383,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥5,281

Average Price Target¥5,281

Lowest Price Target¥5,281

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

¥5,281

Sell

-1.62%

Downside

Reiterated

01/16/26

Hisae Kawamoto

Jefferies

¥5,200→¥5,300

Hold

-1.27%

Downside

Reiterated

10/01/25

Kobayashi Pharma Co Ltd. (4967:JP) PT Raised to JPY5,300 at JefferiesJefferies analyst Hisae Kawamoto raised the price target on Kobayashi Pharma Co Ltd. (4967:JP) to JPY5,300.00 (from JPY5,200.00) while maintaining a Hold rating.

Yuji Ohana

Nomura

¥5,100→¥5,050

Hold

-5.92%

Downside

Reiterated

09/10/25

Kobayashi Pharmaceutical Co (KBYPF) Gets a Hold from Nomura

Unknown Analyst

UBS

Not Ranked

UBS

¥5,600

Hold

4.32%

Upside

Reiterated

03/28/25

UBS Reiterates Neutral Rating on Kobayashi Pharma Co Ltd. (4967:JP)UBS analyst Xuening Wen reiterated a Neutral rating and JPY5,600.00 price target on Kobayashi Pharma Co Ltd. (4967:JP).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

¥5,281

Sell

-1.62%

Downside

Reiterated

01/16/26

Hisae Kawamoto

Jefferies

¥5,200→¥5,300

Hold

-1.27%

Downside

Reiterated

10/01/25

Yuji Ohana

Nomura

¥5,100→¥5,050

Hold

-5.92%

Downside

Reiterated

09/10/25

Kobayashi Pharmaceutical Co (KBYPF) Gets a Hold from Nomura

Unknown Analyst

UBS

Not Ranked

UBS

¥5,600

Hold

4.32%

Upside

Reiterated

03/28/25

UBS Reiterates Neutral Rating on Kobayashi Pharma Co Ltd. (4967:JP)UBS analyst Xuening Wen reiterated a Neutral rating and JPY5,600.00 price target on Kobayashi Pharma Co Ltd. (4967:JP).

Stocks with the Highest Top Analyst Consensus in the Consumer Defensive Sector

xxx

Find stocks in the Consumer Defensive sector that are highly recommended by Top Performing Analysts.

4967 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4967 has received 0 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. 4967 average Analyst price target in the past 3 months is 5,281.00.

Each month's total comprises the sum of three months' worth of ratings.

4967 Financial Forecast

4967 Earnings Forecast

The previous quarter’s earnings for 4967 were -¥42.41.

4967 Sales Forecast

Next quarter’s sales forecast for 4967 is ¥33.00B with a range of ¥32.50B to ¥33.50B. The previous quarter’s sales results were ¥53.70B. 4967 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 52.41% of the time in the same period. In the last calendar year 4967 has Performed in-line its overall industry.

4967 Stock Forecast FAQ

What is JP:4967’s average 12-month price target, according to analysts?

Based on analyst ratings, Kobayashi Pharmaceutical Co Ltd’s 12-month average price target is 5,281.00.

What is JP:4967’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for JP:4967, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Kobayashi Pharmaceutical Co Ltd a Buy, Sell or Hold?

Kobayashi Pharmaceutical Co Ltd has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 0 hold ratings and 1 sell ratings.

What is Kobayashi Pharmaceutical Co Ltd’s share price target?

The average share price target for Kobayashi Pharmaceutical Co Ltd is 5,281.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥5,281.00 ,and the lowest forecast is ¥5,281.00. The average share price target represents -1.62% Decrease from the current price of ¥5,368.

What do analysts say about Kobayashi Pharmaceutical Co Ltd?

Kobayashi Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Kobayashi Pharmaceutical Co Ltd?

To buy shares of JP:4967, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Kobayashi Pharmaceutical Co (4967) Stock Forecast & Price Target

4967 Analyst Ratings

4967 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

4967 Analyst Recommendation Trends

4967 Financial Forecast

4967 Earnings Forecast

4967 Sales Forecast

4967 Stock Forecast FAQ

Detailed List of Analyst Forecasts